Quick Answer
Kymera Therapeutics, Inc. reported Shares Outstanding of 81.32 million shares for fiscal year 2025.
Kymera Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 81.32M | +25.3% |
| 2024 | 64.89M | +16.7% |
| 2023 | 55.59M | +1.0% |
| 2022 | 55.04M | +6.8% |
| 2021 | 51.54M | +15.9% |
| 2020 | 44.48M | +2205.4% |
| 2019 | 1.93M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 71.74M | +10.8% | +1.7% |
| June 30, 2025 | 70.56M | +14.6% | +8.4% |
| March 31, 2025 | 65.11M | +6.1% | +0.3% |
| December 31, 2024 | 64.89M | +17.2% | +0.2% |
| September 30, 2024 | 64.75M | +16.8% | +5.2% |
| June 30, 2024 | 61.57M | +11.2% | +0.4% |
| March 31, 2024 | 61.35M | +11.0% | +10.8% |
| December 31, 2023 | 55.39M | +0.6% | -0.1% |
- Kymera Therapeutics, Inc. showed an increase of +25.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s shares outstanding has grown by 4114.7% (from 1.93 million shares to 81.32 million shares).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: